AN2 Therapeutics (ANTX) stock forecast for 2026
Last update: 06-24-2022, 11:05Sector: Healthcare
The share price of AN2 Therapeutics, Inc. (ANTX) now
What analysts predict:: $None
52-week high/low: $0 / $0
50/200 Day Moving Average: $0 / $0
This figure corresponds to the average price over the previous 50/200 days. For AN2 Therapeutics stocks, the 50-day moving average is the support level today.
For AN2 Therapeutics stocks, the 200-day moving average is the support level today.
Are you interested in AN2 Therapeutics stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the AN2 Therapeutics stock price in 2026. How much will one AN2 Therapeutics share be worth in 2026?
Is it worth taking profit / loss on AN2 Therapeutics stock now or waiting? What are analysts' forecasts for AN2 Therapeutics stock?
We forecast AN2 Therapeutics stock performance using neural networks based on historical data on AN2 Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The AN2 Therapeutics stock prediction results are shown below and presented as a graph, table and text information.
AN2 Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for AN2 Therapeutics analysts is $None.
Today 200 Day Moving Average is the support level (0 $).
50 Day Moving Average is the support level (0 $).
Historical and forecast chart of AN2 Therapeutics stock
The chart below shows the historical price of AN2 Therapeutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the AN2 Therapeutics stock price can be found in the table below.
AN2 Therapeutics (ANTX) Forecast for 2026
AN2 Therapeutics information and performance
AN2 is developing treatments for rare, chronic, and serious infectious diseases. Its initial product candidate is epetraborole, a once-daily oral drug that aims to treat chronic nontuberculous mycobacterial lung disease.
The biotech is the second company to open for trading in March. The first was Akanda (ticker: AKAN), a medical-cannabis company, which listed its shares on March 15, soaring 163% in its debut. Akanda stock is down about 18% from the $10.50 first-day closing price but still up 116% from the $4 IPO price.
AN2 Therapeutics Address
1800 EL CAMINO REAL, SUITE D, MENLO PARK, CA, UNITED STATES
Market Capitalization: 14 636 048 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: 5 450 200 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: 3.962
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: N/A
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: N/A
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: -
Enterprise Value (EV) /Revenue
EV To EBITDA: -
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 3000000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
AN2 Therapeutics price target for 2021 by month
Target values for the price of one AN2 Therapeutics share for Jan 2026.
Pessimistic target level: 10.00
Optimistic target level: 10.84
Target values for the price of one AN2 Therapeutics share for Feb 2026.
Pessimistic target level: 10.58
Optimistic target level: 11.17
Target values for the price of one AN2 Therapeutics share for Mar 2026.
Pessimistic target level: 10.71
Optimistic target level: 11.62
Target values for the price of one AN2 Therapeutics share for Apr 2026.
Pessimistic target level: 10.13
Optimistic target level: 10.99
Target values for the price of one AN2 Therapeutics share for May 2026.
Pessimistic target level: 10.74
Optimistic target level: 11.33
Target values for the price of one AN2 Therapeutics share for Jun 2026.
Pessimistic target level: 10.79
Optimistic target level: 11.38
Target values for the price of one AN2 Therapeutics share for Jul 2026.
Pessimistic target level: 11.30
Optimistic target level: 12.27
Target values for the price of one AN2 Therapeutics share for Aug 2026.
Pessimistic target level: 12.20
Optimistic target level: 13.05
Target values for the price of one AN2 Therapeutics share for Sep 2026.
Pessimistic target level: 12.55
Optimistic target level: 13.54
Target values for the price of one AN2 Therapeutics share for Oct 2026.
Pessimistic target level: 12.63
Optimistic target level: 13.19
Target values for the price of one AN2 Therapeutics share for Nov 2026.
Pessimistic target level: 12.74
Optimistic target level: 13.81
Target values for the price of one AN2 Therapeutics share for Dec 2026.
Pessimistic target level: 12.53
Optimistic target level: 13.63
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.